Reindeer games can't hold RXMD down.
Shorts have to cover, and some investors have been scared out of the water by them, but that doesn't change RXMD's fundamentals.
RXMD continues to deliver on its promises, and as it does it attracts new investors who see it for the gem that it is.
As RXMD achieves its goals of $22 million in 2017 revenues and uplisting (perhaps with a merger/acquisition in the process), you'll see larger and larger investors take an interest, and that's when we all win.
RXMD!